Advancements in Hemophilia Gene Therapy

Research Overview

Researchers from Spark Therapeutics and Pfizer have conducted a study to evaluate the safety and effectiveness of a new gene therapy vector for treating hemophilia B. This condition significantly impacts the body’s ability to stop bleeding and repair damaged blood vessels, primarily due to a deficiency in coagulation factor IX.

Understanding Hemophilia B

Hemophilia B is characterized by a reduced level of factor IX, leading to symptoms such as easy bruising and spontaneous bleeding, particularly from the nose, joints, or urinary tract. Traditional treatment methods have included factor IX transfusions to counteract this deficiency. However, these transfusions can be expensive, time-consuming, and carry risks of immune rejection and infection.

Exploring Gene Therapy as an Alternative

Because hemophilia B arises from an underactive form of the factor IX gene, gene therapy offers a potential alternative. This approach involves inserting a more active version of the gene into a patient’s DNA, thereby enhancing factor IX production.

Trial Results Published

A recent study published in the New England Journal of Medicine presented findings from an early trial of gene therapy. The trial assessed the SPK-9001 therapeutic vector, a modified virus designed to deliver a hyperactive form of the factor IX gene into patients’ DNA. Ten men with severe hemophilia B, all of whom had factor IX levels at 2% of normal or below, participated in the trial. They received an intravenous injection of the vector and were monitored for up to 18 months. Prior to the trial, all participants had been receiving factor IX transfusions—seven for preventative reasons and three as needed.

Key Findings

At the conclusion of the trial, participants exhibited an average factor IX production level of 33.7% of normal. Notably, the frequency of bleeding events decreased significantly, dropping from an average of 11.1 incidents per year to just 0.4. Remarkably, nine out of ten patients reported no bleeding episodes during the trial, and only one individual continued to require factor IX transfusions afterward. Immune reactions to the SPK-9001 vector were minimal, with no serious adverse events recorded; however, one patient did experience temporarily elevated enzyme levels in the liver, where factor IX is produced.

Implications for Future Research

According to the article’s author, these findings mark a significant milestone in hemophilia gene therapy, as challenges related to factor IX production and patient immune responses have hindered progress in prior trials. Larger-scale follow-up studies are needed to confirm these results and establish a comprehensive safety profile for SPK-9001. Should the vector prove to be safe and effective, it could become an essential tool in the treatment of hemophilia B and might also advance gene therapy options for the more prevalent hemophilia A.

References

Schutgens R. Gene therapy in hemophilia: From hype to hope. Hemasphere. 2018;2(2):e37. doi:10.1097/HS9.0000000000000037.

George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215-2227. doi:10.1056/NEJMoa1708538.